On May 5, 2026, Terns Pharmaceuticals, Inc. completed its merger with Merck Sharp & Dohme LLC, with Merck acquiring over 86% of Terns' shares at $53.00 each; Terns now operates as a wholly owned subsidiary of Merck.
AI Assistant
TERNS PHARMACEUTICALS INC
2026
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.